Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02960022 · ClinicalTrials.gov registry record · Phase 2
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
A Phase 2 study of Prostate Cancer, sponsored by Astellas Pharma Global Development.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 900
- Enrollment target
- 20
- Study locations
NCT02960022: Recruiting Phase 2 study of Prostate Cancer, sponsored by Astellas Pharma Global Development.
NCT02960022 is a Phase 2 study of Prostate Cancer that is actively recruiting participants, run by Astellas Pharma Global Development. The registered enrollment target is 900 participants, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (48% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02960022, a Phase 2 study of Prostate Cancer, is actively recruiting participants, sponsored by Astellas Pharma Global Development.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 900 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astellas or Medivation (i.e., parent study) which has completed, at a minimum, the primary analysis or the study specified evaluation period.
Conditions Studied
Interventions
- DRUG enzalutamide
- DRUG abiraterone acetate
- DRUG prednisone
- DRUG Leuprolide acetate
Study Locations (20)
California
- Site US10040 - Los Angeles
- Site US10009 - Los Angeles
- Site US10067 - Orange
- Site US10008 - San Bernardino
- Site US10042 - San Diego
- Site US10028 - Stanford
Colorado
- Site US10001 - Aurora
- Site US10017 - Denver
Florida
- Site US10049 - Daytona Beach
- Site US10048 - Jacksonville
Illinois
- Site US10002 - Chicago
- Springfield Clinic, LLP - Springfield
Kansas
- University of Kansas Medical Center - Kansas City
- Site US10066 - Lenexa
Alaska
- Site US10052 - Anchorage
Arizona
- Site US10011 - Tucson
District of Columbia
- Site US10050 - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2016-12-22 |
| Est. Completion | 2029-07-31 |
| Phase | Phase 2 |
What NCT02960022 shows while recruiting
NCT02960022 is an interventional study that assigns participants to a tested intervention. The registered 900 participants enrollment target is mid-sized for trials with a published cap, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (48% higher).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which enzalutamide is the first listed.
NCT02960022 names 20 study sites across 11 states, led by California, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT02960022 about?
NCT02960022 is a clinical study titled "A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study". The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astellas or Medivation (i.e., parent study) which has completed, at ...
What is the current status of trial NCT02960022?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 900 participants. The study started on 2016-12-22. Estimated completion is 2029-07-31.
What conditions does trial NCT02960022 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT02960022?
The interventions under investigation include: enzalutamide (DRUG), abiraterone acetate (DRUG), prednisone (DRUG), Leuprolide acetate (DRUG).
Who is sponsoring clinical trial NCT02960022?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02960022 being conducted?
This trial has 20 study locations across Alaska, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02960022's enrollment target sits among peer trials
900 72nd of 735 higher than 663 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
-
Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
- NCT02414347 · 900 participants
F 18 T807 Tau PET Imaging of Alzheimer's Disease
- NCT02670408 · 900 participants
Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
- NCT03932786 · 900 participants
Studying Health Outcomes After Treatment in Patients With Retinoblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI